+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The first detection of CTX-M-14 extended-spectrum beta-lactamase among diverse beta-lactamase-producing Proteus mirabilis clinical isolates



The first detection of CTX-M-14 extended-spectrum beta-lactamase among diverse beta-lactamase-producing Proteus mirabilis clinical isolates



Diagnostic Microbiology and Infectious Disease 54(3): 237-239



CTX-M-14- and -2-like extended-spectrum beta-lactamases were detected in 5 and I Protects mirabilis isolates, respectively, among 92 nonduplicate strains tested from December 2002 to September 2003.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012654782

Download citation: RISBibTeXText

PMID: 16427241

DOI: 10.1016/j.diagmicrobio.2005.09.013


Related references

Evaluation of a modified double-disc synergy test for detection of extended spectrum beta-lactamases in AMPC beta-lactamase-producing proteus mirabilis. Indian Journal of Medical Microbiology 26(1): 58-61, 2008

Emergence of multidrug-resistant Klebsiella pneumoniae isolates producing VIM-4 metallo-beta-lactamase, CTX-M-15 extended-spectrum beta-lactamase, and CMY-4 AmpC beta-lactamase in a Tunisian university hospital. Antimicrobial Agents and ChemoTherapy 50(12): 4198-4201, 2006

Evaluation of the MicroScan NegCombo panel Type 44 for detection of extended-spectrum beta-lactamase among clinical isolates of Escherichia coli, Klebsiella species, and Proteus mirabilis. Korean Journal of Laboratory Medicine 29(1): 35-40, 2009

Evaluation of clonal relatedness of extended-spectrum beta-lactamase-producing Proteus mirabilis isolates by quantitative antibiogram and RAPD typing. Clinical Microbiology and Infection 3(1): 45-52, 1997

Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clinical Microbiology and Infection 16(2): 132-136, 2010

CTX-M-1 extended-spectrum beta-lactamase-producing Proteus mirabilis in Greece. Microbial Drug Resistance 11(4): 351-354, 2005

VEB-6 extended-spectrum beta-lactamase-producing Proteus mirabilis from Sultanate of Oman. International Journal of Antimicrobial Agents 34(5): 493-494, 2009

In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrobial Agents and ChemoTherapy 43(5): 1170-1176, 1999

Characteristics of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis. Journal of Infection and ChemoTherapy 19(5): 799-805, 2014

Extended-spectrum-beta-lactamase-producing Proteus mirabilis: laboratory-based surveillance in cooperation with 12 clinical laboratories in the Kinki Region of Japan. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 80(3): 231-237, 2006

Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates. Journal of the College of Physicians and Surgeons--Pakistan 22(6): 358-362, 2012

First detection of VIM-1 type metallo-beta-lactamase in a multidrug-resistant Klebsiella pneumoniae clinical isolate from Turkey also producing the CTX-M-15 extended-spectrum beta-lactamase. Journal of ChemoTherapy 19(4): 467-468, 2007

High frequency of beta-lactam susceptibility in CTX-M-type extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations. Journal of Antimicrobial ChemoTherapy 65(11): 2481-2483, 2011

Novel extended-spectrum TEM-87 beta-lactamase from a proteus mirabilis clinical isolate. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 98, 2000

Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital. Journal of Antimicrobial ChemoTherapy 54(6): 1144-1147, 2004